We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, GlaxoSmithKline (GSK - Free Report) closed at $37.97, marking a +0.34% move from the previous day. This change outpaced the S&P 500's 0.13% loss on the day. Meanwhile, the Dow lost 0.23%, and the Nasdaq, a tech-heavy index, added 0.54%.
Heading into today, shares of the drug developer had lost 3.4% over the past month, lagging the Medical sector's gain of 3.7% and the S&P 500's gain of 3.5% in that time.
GSK will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.67, up 4.69% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $11.47 billion, up 0.07% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.05 per share and revenue of $44.39 billion. These totals would mark changes of -3.79% and +3.13%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for GSK. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.79% higher. GSK is currently a Zacks Rank #3 (Hold).
Investors should also note GSK's current valuation metrics, including its Forward P/E ratio of 12.41. This valuation marks a discount compared to its industry's average Forward P/E of 14.44.
It is also worth noting that GSK currently has a PEG ratio of 2.97. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. GSK's industry had an average PEG ratio of 2.23 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 169, putting it in the bottom 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
In the latest trading session, GlaxoSmithKline (GSK - Free Report) closed at $37.97, marking a +0.34% move from the previous day. This change outpaced the S&P 500's 0.13% loss on the day. Meanwhile, the Dow lost 0.23%, and the Nasdaq, a tech-heavy index, added 0.54%.
Heading into today, shares of the drug developer had lost 3.4% over the past month, lagging the Medical sector's gain of 3.7% and the S&P 500's gain of 3.5% in that time.
GSK will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.67, up 4.69% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $11.47 billion, up 0.07% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.05 per share and revenue of $44.39 billion. These totals would mark changes of -3.79% and +3.13%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for GSK. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.79% higher. GSK is currently a Zacks Rank #3 (Hold).
Investors should also note GSK's current valuation metrics, including its Forward P/E ratio of 12.41. This valuation marks a discount compared to its industry's average Forward P/E of 14.44.
It is also worth noting that GSK currently has a PEG ratio of 2.97. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. GSK's industry had an average PEG ratio of 2.23 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 169, putting it in the bottom 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.